Safety and Efficacy of Fecal Microbiota, Live-jslm to Prevent Recurrent Clostridioides difficile Infection in Participants With Irritable Bowel Syndrome
Aroniadis O, Guthmueller B, Dehlin K, Srivastava S, Feuerstadt P, Lembo A, Weber H. Safety and Efficacy of Fecal Microbiota, Live-jslm to Prevent Recurrent Clostridioides difficile Infection in Participants With Irritable Bowel Syndrome. Infectious Diseases And Therapy 2025, 14: 2157-2169. PMID: 40784972, PMCID: PMC12425869, DOI: 10.1007/s40121-025-01208-0.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsConcurrent IBSStandard-of-careIrritable bowel syndromeSustained clinical responseExploratory subgroup analysisClinical responsePrimary endpointAntibiotic treatmentSerious treatment-emergent adverse eventsTreatment successBowel syndromeRecurrent ClostridioidesOpen-labelCDI recurrenceSingle-doseSecondary endpointsFecal microbiotaEfficacious optionAdverse eventsProspective studyIntroductionThe safetySubgroup analysisFDA approvalRCDI
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply